PsyRx CNS Bio-Tech (XTAE:PSRX) Altman Z-Score

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:PSRX PsyRx CNS Bio-Tech Ltd XTAE:PSRX
10 GF Score
Price ₪0.73
! 1 Warning Sign
View Full Analysis

What is PsyRx CNS Bio-Tech Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

PsyRx CNS Bio-Tech does not have enough data to calculate Altman Z-Score.


PsyRx CNS Bio-Tech  (XTAE:PSRX) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


PsyRx CNS Bio-Tech Altman Z-Score Related Terms


PsyRx CNS Bio-Tech Altman Z-Score Historical Data

* Premium members only.

The historical data trend for PsyRx CNS Bio-Tech's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PsyRx CNS Bio-Tech Altman Z-Score Chart

PsyRx CNS Bio-Tech Annual Data
Trend
Altman Z-Score

PsyRx CNS Bio-Tech Semi-Annual Data
Altman Z-Score

XTAE:PSRX vs ZTS, UTHR, VTRS: Altman Z-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PsyRx CNS Bio-Tech's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PsyRx CNS Bio-Tech Altman Z-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PsyRx CNS Bio-Tech's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where PsyRx CNS Bio-Tech's Altman Z-Score falls into.


XTAE:PSRX
10GF Score
PsyRx CNS Bio-Tech Ltd XTAE:PSRX
Altman Z-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PsyRx CNS Bio-Tech Business Description

Address Arik Einstein 3, Herzliya, ISR, 4610301
PsyRx CNS Bio-Tech Ltd Formerly Cannabotech Ltd is engaged in the research and development of cannabis-based drugs. It is a biomedical company focused on the benefits of cannabinoids and medicinal mushrooms, applying the pure power of nature and science to health issues.
10GF Score

Get the complete analysis for XTAE:PSRX

Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪0.73
Price